Mind the IQGAP Cancer Cell

Slides:

Advertisements

Similar presentations

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Advertisements

Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells Nilay Sethi, Xudong Dai, Christopher.

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

Inflammation and Cancer: IL-6 and STAT3 Complete the Link

Ras Brakes for Hippo Developmental Cell

Charles Swanton, Julian Downward Cancer Cell

“Atypical” Regulation of Hedgehog-Dependent Cancers

NF-κB: A Coordinator for Epigenetic Regulation by MLL

Linking miRNA Regulation to BCR-ABL Expression: The Next Dimension

Taking the Stress out of Melanoma

Nomeda Girnius, Roger J. Davis Cancer Cell

Lymphotoxins: New Targets for Hepatocellular Carcinoma

Wild-Type RAS: Keeping Mutant RAS in CHK

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma Maria Romina Girotti, Filipa Lopes, Natasha.

HSF1 in Translation Cancer Cell

The Ids Have It Cancer Cell

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

A Mitochondrial Power Play in Lymphoma

RAS unplugged: Negative feedback and oncogene-induced senescence

A Big Step for SIRT7, One Giant Leap for Sirtuins… in Cancer

Killing Tumors by Keeping Ras and PI3′ Kinase Apart

A Sweet New Role for EGFR in Cancer

Therapeutic targeting of the tumor microenvironment

Yanxin Pei, Robert J. Wechsler-Reya Cancer Cell

Annapoorni Rangarajan, Sue J. Hong, Annie Gifford, Robert A. Weinberg

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Volume 26, Issue 1, Pages 1-2 (July 2014)

Suppressing NFAT Increases VEGF Signaling in Hemangiomas

Alyson A. Lokken, Nancy J. Zeleznik-Le Cancer Cell

ABT-199: Taking Dead Aim at BCL-2

Volume 13, Issue 1, Pages 1-2 (January 2008)

A Radical Role for p38 MAPK in Tumor Initiation

CALming Down T Cell Acute Leukemia

Fibrinogen in the Nervous System: Glia Beware

MicroRNAs and Parallel Stem Cell Lives

The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?

Raf-1 and Squamous Cell Carcinoma: Rok-ing the Boat

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Vismodegib Resistance in Basal Cell Carcinoma: Not a Smooth Fit

The RAF Inhibitor Paradox Revisited

RalGDS comes of age Cancer Cell

The RAS/MAPK Axis Gets Stressed Out

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis

Hard Times for Oncogenic BRAF-Expressing Melanoma Cells

BMPing Off Glioma Stem Cells

Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK

John D. Gordan, Craig B. Thompson, M. Celeste Simon Cancer Cell

Volume 14, Issue 4, Pages (October 2008)

Mutant BRAF Melanomas—Dependence and Resistance

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma Maria Romina Girotti, Filipa Lopes, Natasha.

To Infinium, and Beyond! Cancer Cell

Volume 10, Issue 3, Pages (September 2006)

All Roads Lead to the Ribosome

Lesley-Ann Martin, Mitch Dowsett Cancer Cell

Co-opted integrin signaling in ErbB2-induced mammary tumor progression

Attacking Cancer at Its Root

There's a Time and a Place for MYCN

c-Raf in KRas Mutant Cancers: A Moving Target

Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Volume 17, Issue 2, Pages (February 2010)

Connecting with an Old Partner in a New Way

Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX Jean-Christophe Marine Cancer Cell Volume.

Anthony N. Imbalzano, Stephen N. Jones Cancer Cell

The Ups and Downs of Src Regulation: Tumor Suppression by Cbp

Ras Brakes for Hippo Developmental Cell

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Presentation transcript:

Mind the IQGAP Cancer Cell Berta Sanchez-Laorden, Amaya Viros, Richard Marais Cancer Cell Volume 23, Issue 6, Pages 715-717 (June 2013) DOI: 10.1016/j.ccr.2013.05.017 Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 IQGAP1 Is a Therapeutic Target in ERK-Pathway-Driven Cancer Cells (A) IQGAP1 forms a signaling complex with RAF, MEK, and ERK. Mutant RAS (∗RAS) or BRAF (∗BRAF) hyperactivates ERK signaling and promotes tumor cell proliferation and survival. Delivery of exogenous WW peptide (WW PEPT) prevents ERK binding to IQGAP1 through its WW domain (WW) and suppresses ERK activity, thereby blocking proliferation in cancer cells that are addicted to the ERK pathway. (B) The scaffold function of IQGAP1 within the ERK pathway is dispensable in normal cell differentiation, growth, and survival. Cancer Cell 2013 23, 715-717DOI: (10.1016/j.ccr.2013.05.017) Copyright © 2013 Elsevier Inc. Terms and Conditions